WHERE HAVE THE PLATELETS GONE? TIROFIBAN INDUCED THROMBOCYTOPENIA
DOI:
https://doi.org/10.47144/phj.v47i1.733Keywords:
Thrombocytopenia, Glycoprotein IIb/IIIa inhibitors, TirofibanAbstract
ABSTRACTGlycoprotein IIb/IIIa inhibitors (GP IIb/IIIa) prevent platelet aggregation by
blocking fibrinogen binding to GP IIb/IIIa receptors on platelets. GP IIb/IIIa
inhibitors have shown to improve clinical outcomes. They are widely used in
patients with acute coronary syndrome and following percutaneous intervention
(PCI). Thrombocytopenia associated with this class of agents is a well-known
complication. Drug dependent antibodies are the cause of thrombocytopenia in
this condition. However, severe thrombocytopenia is rare.
Here we report a case of acute severe thrombocytopenia following treatment with
tirofiban, a GP IIb/IIIa inhibitor in a patient who underwent PCI for ST-elevation
myocardial infarction (STEMI).
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/